Remepy
Remepy develops Hybrid Drugs that combine medicines with adaptive digital treatment protocols.
Operating headquarters
New York, NY, USFounded
2022Remepy develops Hybrid Drugs that combine medicines with adaptive digital treatment protocols.
Remepy's approach integrates medicine and digital treatment into one therapeutic program, allowing both components to be designed around the same clinical objective. Adaptive protocols can provide disease-specific experiences that extend treatment beyond medication administration.
The platform can support multiple therapeutic areas while retaining a common development model. Clinical programs such as Hybridopa provide evidence that can inform how combined interventions are measured and advanced with partners.
Source: remepy.com
Drug developers are exploring ways to combine medicines with software-based interventions that support behavior, adherence, and disease management. Hybrid Drug programs occupy a developing category between conventional pharmaceuticals and stand-alone digital therapeutics.
Remepy's opportunity depends on demonstrating that combined programs produce clinically meaningful effects and fit existing development pathways. Partnerships and disease-specific evidence can broaden adoption across neurological disease, oncology, and women's health.
Source: remepy.com
Remepy's Hybrid Drug Platform supports integrated treatments that pair medicines with adaptive digital protocols. Hybridopa applies the model to Parkinson's disease, while additional product families address oncology and women's health.
Each program coordinates pharmacological treatment with software-guided therapeutic experiences built for a specific disease context. The platform is intended to support development, delivery, and clinical evaluation of the combined intervention.
Source: remepy.com